These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 29424120)

  • 21. Adjustment for unbalanced sample size for analytical biosimilar equivalence assessment.
    Dong XC; Weng YT; Tsong Y
    J Biopharm Stat; 2017; 27(2):220-232. PubMed ID: 28060570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Global regulatory standards for the approval of biosimilars.
    Mounho B; Phillips A; Holcombe K; Grampp G; Lubiniecki T; Mollerup I; Jones C
    Food Drug Law J; 2010; 65(4):819-37, ii-iii. PubMed ID: 24479248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Biosimilars in inflammatory bowel disease].
    Siegmund B; Atreya R; Bokemeyer B; Kruis W; Mudter J; Sander C; Schreiber S; Reindl W; Zeissig S; Kucharzik T
    Z Gastroenterol; 2016 Nov; 54(11):1217-1222. PubMed ID: 27711946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States.
    Teeple A; Ellis LA; Huff L; Reynolds C; Ginsburg S; Howard L; Walls D; Curtis JR
    Curr Med Res Opin; 2019 Apr; 35(4):611-617. PubMed ID: 30712393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biosimilars in the therapy of inflammatory bowel diseases.
    Hlavaty T; Letkovsky J
    Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biosimilars in ulcerative colitis: When and for who?
    Ilias A; Gonczi L; Kurti Z; Lakatos PL
    Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Assessment of Quality Attributes for Biosimilars: a Statistical Perspective on Current Practice and a Proposal.
    Mielke J; Innerbichler F; Schiestl M; Ballarini NM; Jones B
    AAPS J; 2018 Nov; 21(1):7. PubMed ID: 30483892
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epoetin biosimilars in Europe: five years on.
    Mikhail A; Farouk M
    Adv Ther; 2013 Jan; 30(1):28-40. PubMed ID: 23242745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Biosimilars--opportunity or threat?].
    Swierkot J
    Wiad Lek; 2013; 66(2 Pt 2):200-5. PubMed ID: 25775818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The US approach to biosimilars: the long-awaited FDA approval pathway.
    Calvo B; Zuñiga L
    BioDrugs; 2012 Dec; 26(6):357-61. PubMed ID: 23030677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. On safety margin for drug interchangeability.
    Zheng J; Chow SC; Song F
    J Biopharm Stat; 2017; 27(2):293-307. PubMed ID: 27911675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evolution after switching to biosimilar infliximab in inflammatory bowel disease patients in clinical remission.
    Guerrero Puente L; Iglesias Flores E; Benítez JM; Medina Medina R; Salgueiro Rodríguez I; Aguilar Melero P; Cárdenas Aranzana MJ; González Fernández R; Manzanares Martin B; García-Sánchez V
    Gastroenterol Hepatol; 2017 Nov; 40(9):595-604. PubMed ID: 28865888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review.
    McKinnon RA; Cook M; Liauw W; Marabani M; Marschner IC; Packer NH; Prins JB
    BioDrugs; 2018 Feb; 32(1):27-52. PubMed ID: 29344876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community.
    Markus R; Liu J; Ramchandani M; Landa D; Born T; Kaur P
    BioDrugs; 2017 Jun; 31(3):175-187. PubMed ID: 28439817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biosimilars: Practical Considerations for Pharmacists.
    Stevenson JG; Popovian R; Jacobs I; Hurst S; Shane LG
    Ann Pharmacother; 2017 Jul; 51(7):590-602. PubMed ID: 28176529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short article: Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease.
    Binkhorst L; Sobels A; Stuyt R; Westerman EM; West RL
    Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):699-703. PubMed ID: 29538037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are biosimilars patentable?
    Rolfe D; Parker J; Morgan M
    Expert Opin Ther Pat; 2016 Aug; 26(8):871-5. PubMed ID: 27215647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How Similar are Biosimilars? Time to Switch a Position.
    Houri Levi E; Amital H
    Isr Med Assoc J; 2021 Jun; 23(6):376-377. PubMed ID: 34155852
    [No Abstract]   [Full Text] [Related]  

  • 39. [The story of biosimilars--chance or threat?].
    Woroń J; Kocić I
    Pol Merkur Lekarski; 2014 Nov; 37(221):311-5. PubMed ID: 25546996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges.
    Chapman K; Adjei A; Baldrick P; da Silva A; De Smet K; DiCicco R; Hong SS; Jones D; Leach MW; McBlane J; Ragan I; Reddy P; Stewart DI; Suitters A; Sims J
    MAbs; 2016; 8(3):427-35. PubMed ID: 26854177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.